6-溴噻吩并[2,3-d]嘧啶 | 60703-80-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 中文名称: 6-溴噻吩并[2,3-d]嘧啶
• 中文别名: 6-溴噻吩并[2,3-D]嘧啶
• 英文名称: 6-Brom-thieno<2,3-d>pyrimidin
• 英文别名: 6-bromo-thieno[2,3-d]pyrimidine；6-Bromothieno[2,3-d]pyrimidine
• CAS: 60703-80-2
• 化学式: C₆H₃BrN₂S
• 分子量: 215.073
• InChiKey: CCQQNRDRMMVUQI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-溴噻吩并[2,3-d]嘧啶 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 palladium on activated charcoal 、 氢气 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 甲醇 、 水 为溶剂， 反应 35.0h， 生成
  参考文献：
  名称：

  [EN] PROTEIN DEGRADERS AND USES THEREOF
  [FR] AGENTS DE DÉGRADATION DE PROTÉINE ET LEURS UTILISATIONS

  摘要：

  The present invention discloses a protein degrader such as a GSPT1 degrader and use thereof, particularly use in the prevention and/or treatment of diseases.

  公开号：

  WO2023237116A1
• 作为产物：
  描述：

  4-肼基噻吩[2,3-d]嘧啶 在 溴 、 氧气 、 sodium ethanolate 作用下， 生成 6-溴噻吩并[2,3-d]嘧啶
  参考文献：
  名称：

  Robba,M.; Cugnon de Sevricourt,M., Bulletin de la Societe Chimique de France, 1976, p. 761 - 764

  摘要：

  DOI：

文献信息

• THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS
  申请人：Herdewijn Piet

  公开号：US20120046278A1

  公开（公告）日：2012-02-23

  The present invention relates to compound of formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 11 , and R 12 are as defined in the claim 1. The present invention also relates to a method for their preparation, as well as to pharmaceutical compositions thereof. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of disorders and pathologic conditions such as, but not limited to, immune and auto-immune disorders, organ and cells transplant rejections.

  本发明涉及式I、II、III或IV的化合物，及/或其药用可接受的加合盐和/或其立体异构体和/或其溶剂化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R11和R12如权利要求1所定义。本发明还涉及它们的制备方法，以及其药物组合物。本发明进一步涉及所述化合物作为生物活性成分的用途，更具体地作为治疗疾病和病理状况的药物，例如但不限于免疫和自身免疫性疾病、器官和细胞移植排斥反应。
• Thiazolopyrimidine Modulators as Immunosuppressive Agents
  申请人：Herdewijn Piet

  公开号：US20150038494A1

  公开（公告）日：2015-02-05

  The present invention relates to compound of formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 11 , and R 12 are as defined in the claim 1 . The present invention also relates to a method for their preparation, as well as to pharmaceutical compositions thereof. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of disorders and pathologic conditions such as, but not limited to, immune and auto-immune disorders, organ and cells transplant rejections.

  本发明涉及公式I，II，III或IV的化合物，以及/或其药学上可接受的加成盐和/或其立体异构体和/或其溶剂化物，其中R1，R2，R3，R4，R5，R6，R7，R8，R9，R11和R12如权利要求1所定义。本发明还涉及它们的制备方法，以及其药物组合物。本发明还涉及所述化合物作为生物活性成分的用途，更具体地作为治疗疾病和病理状态的药物，例如，但不限于，免疫和自身免疫性疾病，器官和细胞移植排斥。
• Dibenz[B,F]azepine compounds, pharmaceutical compositions comprising same and methods of use thereof
  申请人：Dana-Farber Cancer Institute

  公开号：US07056911B1

  公开（公告）日：2006-06-06

  The invention relates to pharmaceutically active compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention and particularly useful for the treatment or prophylaxis of diseases associated with parasitic infection such as pneumocystis pneumonia, toxoplasmosis, cryptosporidiosis, leischmaniasis and malaria.

  本发明涉及药物活性化合物，以及利用或包含其中一种或多种这样的化合物的治疗方法和药物组合物。本发明的化合物特别适用于治疗或预防与寄生虫感染相关的疾病，如肺孢子菌肺炎、弓形虫病、隐孢子虫病、利什曼病和疟疾。
• Purine analogues and their use as immunosuppressive agents
  申请人：Katholieke Universiteit Leuven, K.U. Leuven R&D

  公开号：EP2923734A1

  公开（公告）日：2015-09-30

  The present invention relates to a compound of formula III or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R7, R8, R9, R11 and R12 are as defined in the claim 1. The present invention also relates to a method for their preparation, as well as to pharmaceutical compositions thereof. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of disorders and pathologic conditions such as, but not limited to, immune and auto-immune disorders, organ and cells transplant rejections.

  本发明涉及一种式 III 或式 IV 的化合物，和/或其药物可接受的加成盐和/或其立体异构体和/或其溶液、 其中 R7、R8、R9、R11 和 R12 如权利要求 1 所定义。 本发明还涉及其制备方法及其药物组合物。本发明还涉及上述化合物作为生物活性成分的用途，更具体地说是作为治疗紊乱和病理状况的药物，例如但不限于免疫和自身免疫紊乱、器官和细胞移植排斥。
• WRN抑制剂
  申请人：苏州浦合医药科技有限公司

  公开号：CN118271323A

  公开（公告）日：2024-07-02

  本发明提供了一种式(I)化合物作为WRN抑制剂，化合物或其药学上可接受的盐、同位素变体、互变异构体或立体异构体。本发明还提供了包含所述化合物的药物组合物，及其在治疗癌症中的用途。#imgabs0#